| Year |
Citation |
Score |
| 2023 |
Bu M, Follett J, Deng I, Tatarnikov I, Wall S, Guenther D, Maczis M, Wimsatt G, Milnerwood A, Moehle MS, Khoshbouei H, Farrer MJ. Inhibition of LRRK2 kinase activity rescues deficits in striatal dopamine physiology in VPS35 p.D620N knock-in mice. Npj Parkinson's Disease. 9: 167. PMID 38110354 DOI: 10.1038/s41531-023-00609-7 |
0.331 |
|
| 2021 |
Abdelmotilib H, Maltbie T, Delic V, Liu Z, Hu X, Fraser KB, Moehle MS, Stoyka L, Anabtawi N, Krendelchtchikova V, Volpicelli-Daley LA, West A. Corrigendum to "α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration" [Neurobiol. Dis., Volume 105 (2017) Article 84, 98]. Neurobiology of Disease. 105506. PMID 34565675 DOI: 10.1016/j.nbd.2021.105506 |
0.475 |
|
| 2017 |
Abdelmotilib H, Maltbie T, Delic V, Liu Z, Hu X, Fraser KB, Moehle MS, Stoyka L, Anabtawi N, Krendelchtchikova V, Volpicelli-Daley LA, West A. α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration. Neurobiology of Disease. PMID 28576704 DOI: 10.1016/J.Nbd.2017.05.014 |
0.339 |
|
| 2015 |
Daher JP, Abdelmotilib HA, Hu X, Volpicelli-Daley LA, Moehle MS, Fraser KB, Needle E, Chen Y, Steyn SJ, Galatsis P, Hirst WD, West AB. LRRK2 Pharmacological Inhibition Abates α-Synuclein Induced Neurodegeneration. The Journal of Biological Chemistry. PMID 26078453 DOI: 10.1074/Jbc.M115.660001 |
0.448 |
|
| 2014 |
Daher JP, Volpicelli-Daley LA, Blackburn JP, Moehle MS, West AB. Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proceedings of the National Academy of Sciences of the United States of America. 111: 9289-94. PMID 24927544 DOI: 10.1073/Pnas.1403215111 |
0.511 |
|
| 2014 |
West AB, Cowell RM, Daher JP, Moehle MS, Hinkle KM, Melrose HL, Standaert DG, Volpicelli-Daley LA. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents. The Journal of Comparative Neurology. 522: 2465-80. PMID 24633735 DOI: 10.1002/Cne.23583 |
0.599 |
|
| 2013 |
Fraser KB, Moehle MS, Daher JP, Webber PJ, Williams JY, Stewart CA, Yacoubian TA, Cowell RM, Dokland T, Ye T, Chen D, Siegal GP, Galemmo RA, Tsika E, Moore DJ, et al. LRRK2 secretion in exosomes is regulated by 14-3-3. Human Molecular Genetics. 22: 4988-5000. PMID 23886663 DOI: 10.1093/Hmg/Ddt346 |
0.567 |
|
| 2012 |
Moehle MS, Webber PJ, Tse T, Sukar N, Standaert DG, DeSilva TM, Cowell RM, West AB. LRRK2 inhibition attenuates microglial inflammatory responses. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 1602-11. PMID 22302802 DOI: 10.1523/Jneurosci.5601-11.2012 |
0.522 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2016 |
Fraser KB, Moehle MS, Alcalay RN, West AB. Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers. Neurology. 86: 994-9. PMID 26865512 DOI: 10.1212/WNL.0000000000002436 |
0.293 |
|
| 2015 |
Moehle MS, Daher JP, Hull TD, Boddu R, Abdelmotilib HA, Mobley J, Kannarkat GT, Tansey MG, West AB. The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins. Human Molecular Genetics. 24: 4250-67. PMID 25926623 DOI: 10.1093/Hmg/Ddv157 |
0.255 |
|
| 2015 |
Moehle MS, West AB. M1 and M2 immune activation in Parkinson's Disease: Foe and ally? Neuroscience. 302: 59-73. DOI: 10.1016/j.neuroscience.2014.11.018 |
0.253 |
|
| 2018 |
Yohn S, Covey D, Foster D, Moehle M, Galbraith J, Cheer J, Lindsley C, Jeffrey Conn P. T227. THE METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 1 REGULATES STRIATAL DOPAMINE RELEASE VIA AN ENDOCANNABINOID-DEPENDENT MECHANISM: IMPLICATIONS FOR THE TREATMENT OF SCHIZOPHRENIA Schizophrenia Bulletin. 44: S204-S205. DOI: 10.1093/Schbul/Sby016.503 |
0.245 |
|
| 2017 |
Moehle MS, Pancani T, Byun N, Yohn SE, Wilson GH, Dickerson JW, Remke DH, Xiang Z, Niswender CM, Wess J, Jones CK, Lindsley CW, Rook JM, Conn PJ. Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor. Neuron. 96: 1358-1372.e4. PMID 29268098 DOI: 10.1016/J.Neuron.2017.12.008 |
0.237 |
|
| 2015 |
Boddu R, Hull TD, Bolisetty S, Hu X, Moehle MS, Daher JP, Kamal AI, Joseph R, George JF, Agarwal A, Curtis LM, West AB. Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury. Human Molecular Genetics. 24: 4078-93. PMID 25904107 DOI: 10.1093/Hmg/Ddv147 |
0.222 |
|
| 2014 |
Liu Z, Galemmo RA, Fraser KB, Moehle MS, Sen S, Volpicelli-Daley LA, DeLucas LJ, Ross LJ, Valiyaveettil J, Moukha-Chafiq O, Pathak AK, Ananthan S, Kezar H, White EL, Gupta V, et al. Unique functional and structural properties of the LRRK2 protein ATP-binding pocket. The Journal of Biological Chemistry. 289: 32937-51. PMID 25228699 DOI: 10.1074/Jbc.M114.602318 |
0.211 |
|
| 2022 |
Bohnen NI, Yarnall AJ, Weil RS, Moro E, Moehle MS, Borghammer P, Bedard MA, Albin RL. Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches. The Lancet. Neurology. PMID 35131038 DOI: 10.1016/S1474-4422(21)00377-X |
0.193 |
|
| 2015 |
Pancani T, Foster DJ, Moehle MS, Bichell TJ, Bradley E, Bridges TM, Klar R, Poslusney M, Rook JM, Daniels JS, Niswender CM, Jones CK, Wood MR, Bowman AB, Lindsley CW, et al. Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice. Proceedings of the National Academy of Sciences of the United States of America. 112: 14078-83. PMID 26508634 DOI: 10.1073/Pnas.1512812112 |
0.174 |
|
| 2019 |
Moehle MS, Conn PJ. Roles of the M acetylcholine receptor in the basal ganglia and the treatment of movement disorders. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 31211471 DOI: 10.1002/mds.27740 |
0.173 |
|
| 2018 |
Yohn SE, Foster DJ, Covey DP, Moehle MS, Galbraith J, Garcia-Barrantes PM, Cho HP, Bubser M, Blobaum AL, Joffe ME, Cheer JF, Jones CK, Lindsley CW, Conn PJ. Activation of the mGlu metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M muscarinic receptor allosteric modulators. Molecular Psychiatry. PMID 30116027 DOI: 10.1038/S41380-018-0206-2 |
0.149 |
|
| 2017 |
Walker AG, Sheffler DJ, Lewis AS, Dickerson JW, Foster DJ, Senter RK, Moehle MS, Lv X, Stansley BJ, Xiang Z, Rook JM, Emmitte KA, Lindsley CW, Conn PJ. Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP, Long-Term Potentiation, and Disrupts Memory Reconsolidation. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 28664928 DOI: 10.1038/Npp.2017.136 |
0.146 |
|
| 2012 |
Moehle MS, Luduena RF, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE. Regional differences in expression of β-tubulin isoforms in schizophrenia. Schizophrenia Research. 135: 181-6. PMID 22264600 DOI: 10.1016/J.Schres.2011.12.010 |
0.134 |
|
| 2021 |
Moehle MS, Bender AM, Dickerson JW, Foster DJ, Qi A, Cho HP, Donsante Y, Peng W, Bryant Z, Stillwell KJ, Bridges TM, Chang S, Watson KJ, O'Neill JC, Engers JL, et al. Discovery of the First Selective M Muscarinic Acetylcholine Receptor Antagonists with Antiparkinsonian and Antidystonic Efficacy. Acs Pharmacology & Translational Science. 4: 1306-1321. PMID 34423268 DOI: 10.1021/acsptsci.0c00162 |
0.111 |
|
| 2023 |
Chambers NE, Millett M, Moehle MS. The muscarinic M4 acetylcholine receptor exacerbates symptoms of movement disorders. Biochemical Society Transactions. 51: 691-702. PMID 37013974 DOI: 10.1042/BST20220525 |
0.104 |
|
| 2023 |
Qi A, Kling HE, Billard N, Rodriguez AL, Peng L, Dickerson JW, Engers JL, Bender AM, Moehle MS, Lindsley CW, Rook JM, Niswender CM. . Molecular Pharmacology. PMID 37595966 DOI: 10.1124/molpharm.122.000643 |
0.071 |
|
| Hide low-probability matches. |